Antisense Oligonucleotide (ASO) Therapeutics Market Size to Reach USD 7,864.9 Million in 2032
The Antisense Oligonucleotide (ASO) Therapeutics Market size was USD 2,355.4 Million in 2024 and is expected to register a revenue CAGR of 16.2% during the forecast period
21st May, 2025 – Rising prevalence of genetic and rare diseases is a key driver driving Antisense Oligonucleotide (ASO) therapeutics market revenue growth. According to the National Institute of Neurological Disorders and Stroke, ALS affects around 1 in 400 persons, or about 0.33% of the population. It is more common in persons aged 40 to 70, with men diagnosed somewhat more frequently than women. A C9orf72 gene deficiency is responsible for around 25-40% of all familial instances (and a small number of sporadic cases). C9orf72 produces a protein present in motor neurons and nerve cells in the brain. Another 12-20% of familial instances are caused by mutations in the SOD1 gene. SOD1 is involved in producing the enzyme copper-zinc superoxide dismutase.
On March 2023, Secarna Pharmaceuticals GmbH & Co. KG, a biopharmaceutical company focused on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address difficult or previously unsolvable targets, and SciNeuro Pharmaceuticals, a leader in the discovery and development of innovative therapeutics for the treatment of neurological diseases, have announced the signing of a multi-target research and option agreement. The businesses will collaborate to develop innovative ASO treatments aimed at targets crucial to Central Nervous System illnesses.
Oligonucleotide-based pharmaceuticals have sparked significant interest as possible therapeutic agents for the treatment of a variety of human disorders; nevertheless, several challenges must be overcome in the development of oligonucleotide-based drugs. These problems include oligonucleotide instability due to enzymatic breakdown and fast renal elimination. While these new developments have rekindled interest in these platforms, a few lingering challenges and preclinical/clinical toxicity issues remain to be addressed, including: proinflammatory effects (vasculitis/inflammatory infiltrates, nephrotoxicity, and hepatotoxicity unrelated to lysosomal accumulation, and thrombocytopenia.
Key Highlights:
- First-generation ASOs segment is expected to register the largest market share over the forecast period. First-generation ASOs modify the phosphate backbone that connects nucleotides. PS oligonucleotides are especially indicative of this initial generation because they are the most extensively used. Chemical changes enhance the stability of ASOs by making them more resistant to nucleases, with the goal of lengthening their half-life. PS changes increase the half-life from minutes to days.
- Neurological disorders segment is expected to account for the largest growth rate over the forecast period. The SMA Foundation estimates that SMA affects 10,000 to 25,000 children and adults in the United States. Only one out of every 6,000 to 10,000 persons is born with the condition. In the United States, roughly one in every fifty persons (or approximately 6 million) has a copy of the mutant SMN1 gene that causes SMA.
- North America accounted for largest market revenue share in the Antisense Oligonucleotide (ASO) therapeutics market in 2024 due to rising prevalence of genetic and rare diseases and advances in nucleic acid chemistry and delivery. On January 2025, Alloy Therapeutics Inc., a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, announced a target-specific collaboration and license agreement with Sanofi to use their novel and proprietary AntiClastic Antisense Platform for a central nervous system (CNS) target. Alloy’s AntiClastic Antisense technology enables drug developers to harness the full potential of antisense treatments by targeting intracellular disease targets at the RNA level.
- Some major companies in the market report include Ionis Pharmaceuticals, Isarna Therapeutics, Regulus Therapeutics, Sarepta Therapeutics, Secarna Pharmaceuticals, Wave Life Sciences, Alloy Therapeutics, Insud Pharma, Bolden Therapeutics, Inc., Merck & Co., Inc., Biogen Inc., Arrowhead Pharmaceuticals, F. Hoffmann-La Roche, Nippon Shinyaku, and Alnylam Pharmaceuticals.
- On February 2025, Cure Rare Disease (CRD) revealed that it has received a grant of USD 5.69 million from the California Institute for Regenerative Medicine (CIRM) to further the development of an antisense oligonucleotide therapy targeting spinocerebellar ataxia type 3 (SCA3), a currently untreatable neurodegenerative disease. Supported by this funding, CRD will focus on scaling up manufacturing, performing IND-enabling toxicology studies, and submitting an Investigational New Drug (IND) application to begin early-stage clinical trials.
- On December 2024, n-Lorem, a nonprofit foundation, and GondolaBio, a clinical-stage biotechnology company founded in 2024 and dedicated to developing novel medicines for patients living with genetic diseases, announced that they have entered multiple collaborations to discover novel antisense oligonucleotide (ASO) medicines for patients who are currently unmet by available treatment options.
Unlock the key to transforming your business strategy with our Antisense Oligonucleotide (ASO) Therapeutics Market Size insights-
Navistrat Analytics has segmented Antisense Oligonucleotide (ASO) Therapeutics market based on type of nucleotide, technology, route of administration, development phase, and indication:
- Type of Nucleotide Outlook (Revenue, USD Million; 2022-2032)
- DNA-based ASOs
- RNA-based ASOs
- Modified/Hybrid ASOs
- Technology Outlook (Revenue, USD Million; 2022-2032)
- First-generation ASOs
- Second-generation ASOs
- Third-generation ASOs
- Conjugated ASOs
- Route of Administration Outlook (Revenue, USD Million; 2022-2032)
- Intrathecal
- Intravenous (IV)
- Subcutaneous
- Intraocular
- Development Phase Outlook (Revenue, USD Million; 2022-2032)
- Preclinical
- Clinical
- Commercial
- Indication Outlook (Revenue, USD Million; 2022-2032)
- Genetic Disorders
- Neurological Disorders
- Oncology
- Neurological Disorders
- Infectious Diseases
- Cardiovascular Diseases
- Others
- Regional Outlook (Revenue, USD Million; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America